NASDAQ:CABA
Cabaletta Bio, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.cabalettabio.comipo date
Oct 25, 2019
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or p...Show More
Earnings
Earnings Release in 12 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus